Brief: Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones
12/01/2026 13:09
Jan 12 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY PROVIDES UPDATES ON CHRONIC HEPATITIS DELTA AND ONCOLOGY PROGRAMS AND UPCOMING 2026 CLINICAL MILESTONES VIR BIOTECHNOLOGY INC: POSITIVE, UPDATED PHASE 2 SOLSTICE DATA SHOWED COMBINATION OF TOBEVIBART AND ELEBSIRAN IS WELL TOLERATED Source text: ID:nBw68mDdla Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO